Novartis

News

Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.

News

Novartis is set to expand the label for its oral BTK inhibitor Rhapsido, keeping the drug on course to become one of its biggest-ever brands.

News

Novartis has started construction of a $1.1bn biomedical research centre in San Diego that will serve as the hub for its R&D operations.

Sales & Marketing

The FDA has signalled increased scrutiny of D2C pharma advertising. So why is pharma stepping up its advertising at Super Bowl LX?

News

Novartis CEO Vas Narasimhan says the company is equipped to ride out "the largest patent expiry" in its history," but 2026 will still be tricky.

News

The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.